Why INmune Bio Inc.’s (INMB) Stock Is Down 6.02%
As of Wednesday, September 23, INmune Bio Inc.’s INMB share price has dipped by 6.02%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Commentary & Analysis
Why INmune Bio Inc.’s (INMB) Stock Is Up 6.35%
As of Tuesday, September 08, INmune Bio Inc.’s INMB share price has surged by 6.35%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why INmune Bio Inc.’s (INMB) Stock Is Up 6.25%
As of Friday, August 21, INmune Bio Inc.’s INMB share price has surged by 6.25%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why INmune Bio Inc.’s (INMB) Stock Is Up 5.92%
As of Wednesday, August 19, INmune Bio Inc.’s INMB share price has surged by 5.92%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why INmune Bio Inc.’s (INMB) Stock Is Up 6.81%
As of Friday, August 07, INmune Bio Inc.’s INMB share price has surged by 6.81%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | INMB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $40.0 | $219.1 | 15% |
|
| Shares Out (Mil) | 26.7 | 53.4 | 35% |
|
| Institutional Ownership | 65.9% | 92.9% | 41% |
|
| Float (Mil) | 27.8 | 41.4 | 34% |
|
| Beta | 0.90 | 0.95 | 53% |
|
| Avg Daily Volume (000s) | 208 | 455 | 46% |
|
| Price Change (52-week) |
(29.0%) | 46.6% | 30% |
|
| Growth | INMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (30.6%) | (10.1%) | 13% |
|
| EPS (5yr) | (13.0%) | 15.8% | 20 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (34.6%) | (15.7%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 1 | |
| Current EPS | ($0.185) | ($0.550) | ($0.430) | |
| Month Ago EPS | ($0.185) | ($0.550) | ($0.490) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.165) | ($0.603) | ($0.525) | |
| Year/Year Chg | 285.4% | (70.4%) | (86.5%) | |
| Financials | INMB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($44) | 24% |
|
| EPS (TTM) | ($0.691) | ($1.600) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($33) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $24 | $174 | 12% |
|
| Valuation | INMB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.76 | 2.11 | 49% |
|
| P/E | na | 20.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | INMB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.0% | na |
|
| Net Margin | na | (70.6%) | na |
|
| ROA | (57.1%) | (47.0%) | 10% |
|
| ROE | (74.8%) | (52.2%) | 12% |
|
| Liabilities to Assets | 24.1% | 29.6% | 16% |
|
| F-Score | 2 | 2 | 7% |
|
INmune Bio Inc. did not pass any screens on 11/3/2026.
